// App-Quantinova.ai

3574 : High-Dose Cytarabine-Based Consolidation Shows Superior Results for Elderly AML Patients with Intermediate Risk Cytogenetics in First Complete Remission

Researchers

Presenter

  • Eshetu G Atenafu

Principal Investigators

  • Vikas Gupta

  • Andre C. Schuh

  • Daniela Cilloni

  • Karen Yee

  • Mark D. Minden

  • Aaron D Schimmer

  • Joseph M. Brandwein

Medical Centers

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada,

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • White Blood Cell

Drug/Treatment

  • Daunorubicin

  • Mitoxantrone

  • Cytarabine liposomal

  • Etoposide

  • Etoposide phosphate

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved